Cargando…
Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry
Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584981/ https://www.ncbi.nlm.nih.gov/pubmed/34768702 http://dx.doi.org/10.3390/jcm10215182 |
_version_ | 1784597579856609280 |
---|---|
author | Ocskay, Klementina Tomescu, Dana Faltlhauser, Andreas Jacob, David Friesecke, Sigrun Malbrain, Manu Kogelmann, Klaus Bogdanski, Ralph Bach, Friedhelm Fritz, Harald Hartjes, Andreas Kortgen, Andreas Soukup, Jens Utzolino, Stefan van Tellingen, Martijn Träger, Karl Schumacher, Ulrike Brunkhorst, Frank M. Molnar, Zsolt |
author_facet | Ocskay, Klementina Tomescu, Dana Faltlhauser, Andreas Jacob, David Friesecke, Sigrun Malbrain, Manu Kogelmann, Klaus Bogdanski, Ralph Bach, Friedhelm Fritz, Harald Hartjes, Andreas Kortgen, Andreas Soukup, Jens Utzolino, Stefan van Tellingen, Martijn Träger, Karl Schumacher, Ulrike Brunkhorst, Frank M. Molnar, Zsolt |
author_sort | Ocskay, Klementina |
collection | PubMed |
description | Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians. Results: Until January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24–72 h) in total. Serum bilirubin levels reduced significantly to −4.6 (95% CI: −6.329 to −2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event. Conclusions: We report the largest case series on hemoadsorption for ‘liver indication’ from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted. |
format | Online Article Text |
id | pubmed-8584981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85849812021-11-12 Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry Ocskay, Klementina Tomescu, Dana Faltlhauser, Andreas Jacob, David Friesecke, Sigrun Malbrain, Manu Kogelmann, Klaus Bogdanski, Ralph Bach, Friedhelm Fritz, Harald Hartjes, Andreas Kortgen, Andreas Soukup, Jens Utzolino, Stefan van Tellingen, Martijn Träger, Karl Schumacher, Ulrike Brunkhorst, Frank M. Molnar, Zsolt J Clin Med Article Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians. Results: Until January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24–72 h) in total. Serum bilirubin levels reduced significantly to −4.6 (95% CI: −6.329 to −2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event. Conclusions: We report the largest case series on hemoadsorption for ‘liver indication’ from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted. MDPI 2021-11-05 /pmc/articles/PMC8584981/ /pubmed/34768702 http://dx.doi.org/10.3390/jcm10215182 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ocskay, Klementina Tomescu, Dana Faltlhauser, Andreas Jacob, David Friesecke, Sigrun Malbrain, Manu Kogelmann, Klaus Bogdanski, Ralph Bach, Friedhelm Fritz, Harald Hartjes, Andreas Kortgen, Andreas Soukup, Jens Utzolino, Stefan van Tellingen, Martijn Träger, Karl Schumacher, Ulrike Brunkhorst, Frank M. Molnar, Zsolt Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry |
title | Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry |
title_full | Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry |
title_fullStr | Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry |
title_full_unstemmed | Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry |
title_short | Hemoadsorption in ‘Liver Indication’—Analysis of 109 Patients’ Data from the CytoSorb International Registry |
title_sort | hemoadsorption in ‘liver indication’—analysis of 109 patients’ data from the cytosorb international registry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584981/ https://www.ncbi.nlm.nih.gov/pubmed/34768702 http://dx.doi.org/10.3390/jcm10215182 |
work_keys_str_mv | AT ocskayklementina hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT tomescudana hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT faltlhauserandreas hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT jacobdavid hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT frieseckesigrun hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT malbrainmanu hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT kogelmannklaus hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT bogdanskiralph hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT bachfriedhelm hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT fritzharald hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT hartjesandreas hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT kortgenandreas hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT soukupjens hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT utzolinostefan hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT vantellingenmartijn hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT tragerkarl hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT schumacherulrike hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT brunkhorstfrankm hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry AT molnarzsolt hemoadsorptioninliverindicationanalysisof109patientsdatafromthecytosorbinternationalregistry |